Volume 71, Issue 4
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645


Classic techniques for detecting the susceptibility of to different drugs are time-consuming, laborious, and require the use of macrophages. The use of flow cytometry for monitoring susceptibility to drugs is beginning to be implemented. Using green fluorescent protein (GFP), we have improved and simplified the screening procedure. We introduced a GFP marker into field strains of causing kala-azar (visceral leishmaniasis) and explored the suitability of transgenic promastigotes that constitutively express GFP in their cytoplasm as target cells for screening of anti-leishmanial drugs.


Article metrics loading...

Loading full text...

Full text loading...



  1. Berman JD, 1991. Clinical diagnostic and chemical developments in the last 10 years. Clin Infect Dis 24 : 684–703.
  2. Desjeux P, 2001. The increase in risk factors for leishmaniasis world-wide. Trans R Soc Trop Med Hyg 95 : 239–243.
  3. Buckner FS, Verlinde CL, La Flamme AC, van Voorhis WC, 1996. Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing beta-galactosidase. Antimicrob Agents Chemother 40 : 2592–2597.
  4. Collins LA, Torrero MN, Franzblau SG, 1998. Green fluorescent protein reporter microplate assay for high-throughput screening of compounds against Mycobacterium tuberculosis. Anti-microb Agents Chemother 42 : 344–347.
  5. McFadden DC, Seeber F, Boothroyd JC, 1997. Use of Toxo-plasma gondii expressing beta-galactosidase for colorimetric assessment of drug activity in vitro. Antimicrob Agents Chemother 41 : 1849–1853.
  6. Roy G, Dumas C, Sereno D, Wu Y, Singh AK, Tremblay MJ, Ouellette M, Olivier M, Papadopoulou B, 2000. Episomal and stable expression of the luciferase reporter gene for quantifying Leishmania spp. infections in macrophages and in animal models. Mol Biochem Parasitol 110 : 195–206.
  7. Chalfie M, Tu Y, Euskirchen G, Ward WW, Prasher DC, 1994. Green fluorescent protein as a marker for gene expression. Science 263 : 802–805.
  8. Singh N, 2002. Is there true Sb (V) resistance in Indian kala azar field isolates? Curr Sci 83 : 101–102.
  9. Ha DS, Schwarz JK, Turco SJ, Beverley SM, 1996. Use of the green fluorescent protein as a marker in transfected Leishmania. Mol Biochem Parasitol 77 : 57–64.
  10. Singh N, Singh RT, Sundar S, 2002. Identification of a gene linked to drug resistance in field isolates of Leishmania donovani. Ann Trop Med Parasitol 96 : 839–841.
  11. Ganguly NK, 2002. Oral miltefosine may revolutionize treatment of visceral leishmaniasis. TDR News 68 : 2.
  12. Thakur CP, 1993. Diminishing effectiveness of currently used drugs in treatment of kala azar and amphotericin B in antimony and pentamidine resistant kala azar. Bhaduri, AN, Basu MK, Sen AK, Kumar S, eds. Current Trends in Leishmania Research. New Delhi: Publications and Information Directorate, Council of Scientific and Industrial Research, 254–262.
  13. Narain L, Dutta GP, 1978. Cultivation and in vitro chemotherapeutic studies on Leishmania donovani. Indian J Parasitol 2 : 83–86.
  14. de Jimenez G, Ercoli N, 1965. Effect of drugs on various leishmania isolates and succinic dehydrogenase inhibition. Exp Parasitol 17 : 302–308.
  15. Lira R, Sundar S, Makharia A, Kenney R, Gam A, Saraiva E, Sacks D, 1999. Evidence that the high incidence of treatment failures in Indian kala azar is due to the emergence of antimony resistant strains of Leishmania donovani. J Infect Dis 180 : 564–567.

Data & Media loading...

  • Received : 29 Jul 2003
  • Accepted : 09 Nov 2003

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error